Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 11Pancreatic Neoplasms 6Nasopharyngeal Carcinoma 5Cholangiocarcinoma 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Colonic Neoplasms 3Cirrhosis, Familial, with Pulmonary Hypertension 3Stomach Neoplasms 2Neoplasm Metastasis 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Neuroendocrine 2Urinary Bladder Neoplasms 1Rare Tumour 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasms, Second Primary 1Neoplasms 1Neoplasm, Residual 1Neoadjuvant Chemotherapy 1Muscle Neoplasms 1Locally Advanced Low Rectal Adenocarcinoma 1Liver Neoplasms 1Liver Metastases of Colorectal Cancer 1Keratosis, Actinic 1HER2-positive Gastric Cancer 1Gastrointestinal Neoplasms 1

Interventions

Trastuzumab 3Oxaliplatin 3Capecitabine 2disitamab vedotin 1Tegafur 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × HER2-positive Gastric Cancer × Fluorouracil × Clear all
NCT07332533 2026-01-12

A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer

Shanghai JMT-Bio Inc.

Phase 2/3 Not yet recruiting
490 enrolled
Gastrointestinal

HER2-positive Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡